You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

EIGHT, the global educational initiative on Hemophilia A and its treatment

Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

read more 

EVENTS

Kedrion Biopharma participates in the Mother and Child Conference in Moscow

A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

read more 

EVENTS

Kedrion Joins Annual PNS Conference on Neurology

The company took part in the event with a booth and a delegation of 40 int’l guests

read more 

  1. CORPORATE - 10-01-2018

    Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

    Goal is to improve access to replacement therapies for coagulation disorders in Europe

    read more 

  2. EVENTS - 09-11-2017

    Kedrion Biopharma joins IPOPI in supporting patients with APP PID Genius

    This new APP, presented at the IPIC Congress in Dubai, will be the personal assistant to people living with PIDs

    read more 

  3. CORPORATE - 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells

    read more 

  4. CORPORATE - 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 

Pages

For more information please contact: pressoffice@kedrion.com